Search 

About TOT BIOPHARM International Company Limited
(HKG:1875)

TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.

The Group has in place three major integrated technology platforms:

Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;

Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;

Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.

Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.